INDINAVIR/ RITONAVIR/ AMPRENAVIR REGIMEN IN HIV

HIV 患者的印地那韦/利托那韦/安普那韦治疗方案

• 批准号: 7376381
• 负责人: Ighovwerha Ofotokun
• 金额: $ 0.38万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7376381
• 关键词: INDINAVIR; RITONAVIR; AMPRENAVIR; REGIMEN; HIV

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a pharmacokinetic pilot study to investigate drug interactions of three protease inhibitors used in HIV infections. It will evaluate the impact of the addition of fos-APV on the pharmacokinetic parameters, the peak aconcentrations, the elimination half-life, and the area under the concentration-time curve of Indinavir, Ritonavir/Amprenavir at steady state in HIV infected patients.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。这是一项药代动力学初步研究，旨在研究用于HIV感染的三种蛋白酶抑制剂的药物相互作用。本研究将评价加入fos-APV对HIV感染者中茚地那韦、利托那韦/安普那韦稳态药代动力学参数、峰浓度、消除半衰期和浓度-时间曲线下面积的影响。